In: Columbus Venture Partners

Viralgen Vector Core will be the Gene Therapy reference in Spain
18/09/2018

The president of the Basque Government, Iñigo Urkullu, has chaired the inauguration ceremony of Viralgen Vector Core, the first plant of... Read More
Aura Biosciences presents Interim Phase 1b/2 Data at the ASRS Annual Meeting
26/07/2018

  Aura Biosciences Presents Interim Phase 1b/2 Data at the American Society of Retina Specialists (ASRS) Annual Meeting CAMBRIGE. USA. July... Read More
Aura Biosciences announces Update of Clinical Safety Efficacy
20/06/2018

  Aura Biosciences Announces Update of Clinical Safety and Efficacy Data on Lead Candidate AU-011 for Choroidal Melanoma CAMBRIGE. USA. June... Read More
Aura Biosciences Completes $30 Million Series C Financing
26/12/2017

CAMBRIDGE. 21 December 2017– Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer…

Read More
Aura Biosciences announces Interim Phase 1b/2 Data on Light-Activated AU-011 for Primary Ocular Melanoma
14/11/2017

Light-activated viral nanoparticle for treatment of choroidal melanoma meets early study endpoints NEW ORLEANS. USA. 12 November 2017— Choroidal melanoma has... Read More
New Clinical Data from Aura Biosciences to be Featured in Presentation at the American Academy of Ophthalmology 2017 Annual Meeting
26/10/2017

Aura Biosciences announced a late-breaking session in AAO 2017 to highlight Phase 1b Clinical Safety Study for the treatment of primary... Read More
Biomimetic motivates the Open Innovation in the dermatology sector
24/10/2017

BIOMIMETIC organize a coworking workday with customers, contributors and the industrial sector, with the participation of international experts in the field... Read More
AskBio and Columbus Venture Partners launch Gene Therapy Company Viralgen
19/10/2017

New vector core facility will be located in San Sebastián, Spain USA, CHAPEL HILL, October 17, 2017 - Asklepios BioPharmaceutical, Inc.... Read More
Vivet Therapeutics named as one of the “Fierce 15” Biothec Companies of 2017 by FierceBiothec
03/10/2017

Vivet Therapeutics is the only European Company that has been chosen as one of the “Fierce 15”, the final fifteen companies... Read More
The Basque Country receive a unique gene therapy production center in Europe
25/09/2017

The investment fund Columbus Venture Partners and the American company Asklepios Biopharmaceutical merge in the joint venture "Viralgen Vector Core" to... Read More